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Purpose: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are acute-onset mucocutaneous diseases
induced by infectious agents and/or inciting drugs. Although the pathobiological mechanisms underlying the onset of SJS/
TEN have not been fully established, the extreme rarity of cutaneous and ocular surface reactions to drug therapies led us
to suspect individual susceptibility. Our previous study of polymorphisms in the HLA-class I genes of 40 Japanese SJS/
TEN patients with ocular surface complications showed that in the Japanese, HLA-A*0206 was strongly associated with
SJS/TEN. In this study, we investigated the association between HLA class II antigens in addition to HLA class I antigens
and SJS/TEN.
Methods: We studied the histocompatibility antigen genes, HLA-A, B, C, DRB1, and DQB1, of 71 Japanese SJS/TEN
patients with ocular complications. We also genotyped 113 healthy volunteers for HLA-A, B, C, DRB1, and DQB1. We
performed polymerase chain reaction amplification followed by hybridization with sequence-specific oligonucleotide
probes (PCR-SSO) using commercial bead-based typing kits.
Results: HLA-A*0206 was strongly associated with SJS/TEN. HLA-A*1101 was inversely associated. HLA-B*5901
exhibited a high odds ratio for SJS/TEN with ocular complications. However, when we corrected the p-value for the
number of alleles detected (n=29), the results ceased to be significant. There was no association between HLA-C and SJS/
TEN. There was also no significant association between HLA-DRB1 and SJS/TEN. HLA-DQB1*0502 was negatively
and weakly associated with SJS/TEN although correction of the p-value for the number of alleles detected rendered the
result not significant.
Conclusions: Because our findings are completely different from data reported on Caucasian patients, they suggest strong
ethnic differences in the HLA-SJS associations.
Stevens-Johnson syndrome (SJS), an acute inflammatory
vesiculobullous reaction of the skin and mucous membranes
first  described  in  1922  [1],  is  commonly  associated  with
infectious agents and/or inciting drugs [2,3]. In patients with
extensive skin detachment and a poor prognosis, the condition
is  called  toxic  epidermal  necrolysis  (TEN)  [4].  Although
erythema multiforme (EM), SJS, and TEN were formerly
accepted as part of a single “EM spectrum,” a retrospective
analysis of the type and distribution of skin lesions and the
extent of epidermal detachment identified EM major and SJS/
TEN as two separate clinical entities that differed with respect
to  histopathologic  changes  and  etiology  [5].  The  annual
incidence of SJS and TEN has been estimated as 0.4–1 and 1–
6 cases per million persons, respectively [3,6]; the mortality
rate is 3% and 27%, respectively [7]. Although rare, these
reactions carry high morbidity and mortality rates and often
result in severe and definitive sequelae such as vision loss.
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The pathobiological mechanisms underlying the onset of SJS/
TEN have not been fully established although the involvement
of  immune  mechanisms  [8,9],  especially  altered  drug
metabolism  [10]  and  infections  such  as  Mycoplasma
pneumoniae [11], has been suggested. The extreme rarity of
cutaneous and ocular surface reactions to drug therapies led
us to suspect individual susceptibility.
In  the  acute  stage,  SJS/TEN  patients  manifest  severe
conjunctivitis and persistent corneal epithelial defects due to
ocular  surface  inflammation  with  vesiculobullous  skin
lesions. In the chronic stage, ocular surface complications,
such as conjunctival invasion into the cornea due to corneal
epithelial  stem  cell  deficiency,  symblepharon,
ankyloblepharon, and in some instances, keratinization of the
ocular surface, persist despite the healing of the skin lesions
[12]. Moreover, we observed that more than 95% of patients
with  SJS/TEN  with  ocular  complications  had  lost  their
fingernails  in  the  acute  or  sub-acute  stage  and  that  some
continue to have transformed nails even after the healing of
their  skin  lesions  [2,13].  SJS/TEN  is  one  of  the  most
devastating ocular surface diseases, leading to corneal damage
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550and  loss  of  vision.  The  reported  incidence  of  ocular
complications in SJS/TEN is 50%–68% [3,7]. In this study,
we focused on patients with SJS/TEN accompanied by ocular
surface complications.
Our previous study of polymorphisms in the HLA-class
I genes (HLA-A, B, C) of 40 Japanese SJS/TEN patients with
ocular surface complications showed that in the Japanese,
HLA-A*0206 was strongly associated with SJS/TEN with
ocular surface complications [13]. We also documented that
in  Japanese  SJS/TEN  patients  with  ocular  surface
complications  there  was  an  association  with  TLR3
polymorphisms [2] and with IL4R polymorphisms [14]. Thus,
genetic factors play an important role in an integrated etiology
of SJS/TEN. However, HLA class II gene polymorphisms of
Japanese SJS/TEN patients have not yet been reported.
Under  the  hypothesis  of  an  immunologic  reaction  in
susceptible individuals, we studied HLA class II (DRB1 and
DQB1) gene polymorphisms in addition to HLA class I (HLA-
A, B, C) in 71 Japanese SJS/TEN patients with ocular surface
complications.
TABLE 1. HLA-A ALLELES AND SJS/TEN WITH OCULAR COMPLICATIONS.
HLA-A
alleles

















*0101 0 0.035 0.16 - 0 0.018 0.3 -
(0/71) (4/113) (0/142) (4/226)
*0201 0.268 0.221 0.47 - 0.155 0.111 0.22 -
(19/71) (25/113) (22/142) (25/226)
*0206 0.423 0.15 0.00004 4.1 0.225 0.084 0.0001 3.2
(30/71) (17/113) * (32/142) (19/226) *
*0207 0.07 0.08 1 - 0.035 0.04 1 -
(5/71) (9/113) (5/142) (9/226)
*0301 0.014 0 0.39 - 0.007 0 0.39 -
(1/71) (0/113) (1/142) (0/226)
*1101 0.056 0.204 0.005 0.23 0.028 0.115 0.003 0.22
(4/71) (23/113) (4/142) (26/226) *
*2402 0.521 0.566 0.55 - 0.296 0.332 0.47 -
(37/71) (64/113) (42/142) (75/226)
*2601 0.099 0.115 0.81 - 0.049 0.062 0.65 -
(7/71) (13/113) (7/142) (14/226)
*2602 0.056 0.035 0.49 - 0.028 0.018 0.49 -
(4/71) (4/113) (4/142) (4/226)
*2603 0.014 0.027 1 - 0.007 0.013 1 -
(1/71) (3/113) (1/142) (3/226)
*3001 0.014 0.009 1 - 0.007 0.004 1 -
(1/71) (1/113) (1/142) (1/226)
*3101 0.099 0.186 0.14 - 0.049 0.093 0.16 -
(7/71) (21/113) (7/142) (21/226)
*3303 0.225 0.212 0.84 - 0.113 0.111 0.95 -
(16/71) (24/113) (16/142) (25/226)
HLA-A*0206 was strongly associated with SJS/TEN with
ocular  complications  (carrier  frequency:  p<0.00005,
corrected  p  value  (Pc)<0.0005,  OR=4.1;  allele  frequency:
p<0.0005, Pc<0.005, OR=3.2). HLA-A*1101 was inversely
associated  (carrier  frequency:  p<0.01,  Pc=0.07,  OR=0.23;
allele  frequency:  p<0.005,  Pc<0.05,  OR=0.22).  SJS/TEN
patients in this study consisted of 40 previously analyzed
patients and 31 new patients. These results validate the strong
association  between  HLA-A*0206  and  SJS/TEN  that  we
reported previously [13].
METHODS
Patients: This study was approved by the Institutional Review
Board of Kyoto Prefectural University of Medicine, Kyoto,
Japan.  All  experimental  procedures  were  conducted  in
accordance  with  the  principles  set  forth  in  the  Helsinki
Declaration. The purpose of the research and the experimental
protocols were explained to all participants, and their written
informed consent was obtained.
TABLE 2. HLA-B ALLELES AND SJS/TEN WITH OCULAR COMPLICATIONS.
HLA-B
alleles













*0702 0.113 0.106 1 - 0.056 0.053 1 -
(8/71) (12/113) (8/142) (12/226)
*1301 0.07 0.027 0.26 - 0.035 0.013 0.27 -
(5/71) (3/113) (5/142) (3/226)
*1302 0 0.009 1 - 0 0.004 1 -
(0/71) (1/113) (0/142) (1/226)
*1501 0.042 0.115 0.11 - 0.028 0.058 0.21 -
(3/71) (13/113) (4/142) (13/226)
*1511 0 0.009 1 - 0 0.004 1 -
(0/71) (1/113) (0/142) (1/226)
*1518 0.014 0.035 0.65 - 0.007 0.018 0.65 -
(1/71) (4/113) (1/142) (4/226)
*1527 0.014 0 0.39 - 0.007 0 0.39 -
(1/71) (0/113) (1/142) (0/226)
*2704 0.014 0 0.39 - 0.007 0 0.39 -
(1/71) (0/113) (1/142) (0/226)
*3501 0.211 0.15 0.29 - 0.106 0.084 0.49 -
(15/71) (17/113) (15/142) (19/226)
*3701 0 0.027 0.29 - 0 0.013 0.29 -
(0/71) (3/113) (0/142) (3/226)
*3802 0 0.009 1 - 0 0.004 1 -
(0/71) (1/113) (0/142) (1/226)
*3901 0.085 0.071 0.78 - 0.042 0.035 0.78 -
(6/71) (8/113) (6/142) (8/226)
*3902 0.014 0.018 1 - 0.007 0.009 1 -
(1/71) (2/113) (1/142) (2/226)
*4001 0.169 0.124 0.39 - 0.092 0.062 0.29 -
(12/71) (14/113) (13/142) (14/226)
*4002 0.127 0.133 1 - 0.07 0.066 0.88 -
(9/71) (15/113) (10/142) (15/226)
*4003 0.014 0 0.39 - 0.007 0 0.39 -
(1/71) (0/113) (1/142) (0/226)
*4006 0.099 0.097 1 - 0.049 0.049 1 -
(7/71) (11/113) (7/142) (11/226)
*4402 0.014 0 0.39 - 0.007 0 0.39 -
(1/71) (0/113) (1/142) (0/226)
*4403 0.225 0.204 0.72 - 0.12 0.106 0.69 -
(16/71) (23/113) (17/142) (24/226)
*4601 0.085 0.115 0.62 - 0.042 0.062 0.49 -
(6/71) (13/113) (6/142) (14/226)
*4801 0.028 0.088 0.13 - 0.014 0.044 0.14 -
(2/71) (10/113) (2/142) (10/226)
*5101 0.197 0.124 0.18 - 0.113 0.066 0.12 -
(14/71) (14/113) (16/142) (15/226)
*5102 0.028 0.009 0.56 - 0.014 0.004 0.56 -
(2/71) (1/113) (2/142) (1/226)
*5201 0.127 0.212 0.17 - 0.07 0.115 0.16 -
(9/71) (24/113) (10/142) (26/226)
*5401 0.042 0.133 0.07 - 0.021 0.066 0.08 -
(3/71) (15/113) (3/142) (15/226)
*5502 0.028 0.044 0.71 - 0.014 0.022 0.71 -
(2/71) (5/113) (2/142) (5/226)
*5601 0.028 0.027 1 - 0.014 0.013 1 -
(2/71) (3/113) (2/142) (3/226)
*5901 0.113 0.018 0.01 7 0.056 0.009 0.02 6.7
(8/71) (2/113) (8/142) (2/226)
*6701 0 0.035 0.16 - 0 0.018 0.3 -
(0/71) (4/113) (0/142) (4/226)
HLA-B*5901 exhibited a high odds ratio for SJS/TEN with
ocular  complications  (carrier  frequency:  p<0.05,  Pc=0.42,
OR=7.0;  allele  frequency:  p<0.05,  Pc=0.46,  OR=6.7).
However, when we corrected the p-value for the number of
alleles detected (n=29), the results ceased to be significant.
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551For HLA genotyping, we enrolled 71 Japanese patients
with SJS/TEN in the chronic or sub-acute phase; all presented
with ocular surface complications. The diagnosis of SJS/TEN
was based on a confirmed history of acute-onset high fever,
serious  mucocutaneous  illness  with  skin  eruptions,  and
involvement of at least two mucosal sites including the ocular
surface. The average patient age was 45.8 ± 17.4 years; the
male:female ratio was 31:40.
Controls: The normal control group consisted of 113 healthy
volunteer blood donors for HLA class I (A, B, C) and HLA
class II (DRB1, DQB1) for genotyping. All volunteers were
Japanese residing in Japan.
HLA genotyping: We studied the histocompatibility antigen
genes HLA-A, B, C, DRB1, and DQB1 of 71 Japanese SJS/
TEN patients with ocular complications. We also genotyped
113 healthy volunteers for HLA-A, B, C, DRB1, and DQB1.
These alleles were detected by the polymerase chain reaction
(PCR)-Luminex typing method using the WAKFlow HLA
typing kit (Wakunaga, Hiroshima, Japan). First, the target
DNA  was  amplified  by  polymerase  chain  reactions  with
biotinylated  primers  specifically  designed  for  each  HLA
locus. Then, the PCR product was denatured and hybridized
to  complementary  oligonucleotide  probes  immobilized  on
fluorescent  coded  microsphere  beads.  At  the  same  time,
biotinylated PCR product was labeled with phycoerythrin-
conjugated streptavidin and immediately examined with the
Luminex  100  system.  Genotype  determination  and  data
analysis were performed automatically, using the WAKFlow
typing software.
TABLE 3. HLA-C ALLELES AND SJS/TEN WITH OCULAR COMPLICATIONS.
HLA-C
alleles













*0102 0.268 0.327 0.4 - 0.141 0.168 0.48 -
(19/71) (37/113) (20/142) (38/226)
*0303 0.239 0.168 0.24 - 0.12 0.093 0.41 -
(17/71) (19/113) (17/142) (21/226)
*0304 0.366 0.23 0.046 1.9 0.197 0.124 0.057 -
(26/71) (26/113) (28/142) (28/226)
*0401 0.07 0.115 0.45 - 0.035 0.058 0.46 -
(5/71) (13/113) (5/142) (13/226)
*0501 0.014 0 0.39 - 0.007 0 0.39 -
(1/71) (0/113) (1/142) (0/226)
*0602 0 0.035 0.16 - 0 0.018 0.3 -
(0/71) (4/113) (0/142) (4/226)
*0702 0.211 0.212 0.99 - 0.12 0.119 0.99 -
(15/71) (24/113) (17/142) (27/226)
*0704 0.014 0.018 1 - 0.007 0.009 1 -
(1/71) (2/113) (1/142) (2/226)
*0801 0.099 0.168 0.28 - 0.049 0.088 0.22 -
(7/71) (19/113) (7/142) (20/226)
*0803 0.028 0.053 0.71 - 0.014 0.027 0.71 -
(2/71) (6/113) (2/142) (6/226)
*1202 0.127 0.212 0.17 - 0.07 0.115 0.16 -
(9/71) (24/113) (10/142) (26/226)
*1402 0.141 0.097 0.37 - 0.078 0.053 0.35 -
(10/71) (11/113) (11/142) (12/226)
*1403 0.225 0.204 0.72 - 0.113 0.106 0.85 -
(16/71) (23/113) (16/142) (24/226)
*1502 0.099 0.044 0.22 - 0.049 0.022 0.23 -
(7/71) (5/113) (7/142) (5/226)
There was no association between HLA-C and SJS/TEN with
ocular complications.
Statistical methods: For statistical analysis to compare carrier
frequency  and  gene  frequency,  we  used  the  χ2-test  for
statistical analysis when the sample number was 10 and more
than 10 and used the Fischer’s exact test when the sample
number was less than 10. The odds ratio (OR) with 95%
confidence intervals (95% CI) was calculated using Labo
Server software (World Fusion, Tokyo, Japan). Each allele
was assessed as an independent variable and separate p values
were  calculated.  A  p  value  of  <0.05  was  regarded  as
significant. In addition, the p values were corrected for the
number of alleles tested.
RESULTS
As shown in Table 1, HLA-A*0206 was strongly associated
with SJS/TEN with ocular complications (carrier frequency:
p<0.00005, corrected p value (Pc)<0.0005, OR=4.1; allele
TABLE 4. HLA-DRB1 ALLELES AND SJS/TEN WITH OCULAR COMPLICATIONS.
HLA-DRB1
alleles













*0101 0.113 0.097 0.81 - 0.056 0.049 0.81 -
(8/71) (11/113) (8/142) (11/226)
*0401 0.028 0.018 0.64 - 0.014 0.009 0.64 -
(2/71) (2/113) (2/142) (2/226)
*0403 0.028 0.053 0.71 - 0.014 0.031 0.49 -
(2/71) (6/113) (2/142) (7/226)
*0404 0.014 0.009 1 - 0.007 0.004 1 -
(1/71) (1/113) (1/142) (1/226)
*0405 0.197 0.248 0.43 - 0.106 0.131 0.44 -
(14/71) (28/113) (15/142) (30/226)
*0406 0.028 0.062 0.49 - 0.014 0.031 0.49 -
(2/71) (7/113) (2/142) (7/226)
*0407 0 0.035 0.16 - 0 0.018 0.3 -
(0/71) (4/113) (0/142) (4/226)
*0410 0.028 0.018 0.64 - 0.014 0.009 0.64 -
(2/71) (2/113) (2/142) (2/226)
*0701 0.014 0.009 1 - 0.007 0.004 1 -
(1/71) (1/113) (1/142) (1/226)
*0802 0.113 0.062 0.27 - 0.056 0.031 0.28 -
(8/71) (7/113) (8/142) (7/226)
*0803 0.239 0.133 0.06 - 0.12 0.071 0.11 -
(17/71) (15/113) (17/142) (16/226)
*0901 0.301 0.31 1 - 0.176 0.168 0.84 -
(22/71) (35/113) (25/142) (38/226)
*1001 0 0.009 1 - 0 0.004 1 -
(0/71) (1/113) (0/142) (1/226)
*1101 0.07 0.027 0.26 - 0.035 0.013 0.27 -
(5/71) (3/113) (5/142) (3/226)
*1201 0.028 0.062 0.49 - 0.014 0.031 0.49 -
(2/71) (7/113) (2/142) (7/226)
*1202 0.085 0.035 0.19 - 0.042 0.018 0.19 -
(6/71) (4/113) (6/142) (4/226)
*1301 0.014 0.009 1 - 0.007 0.004 1 -
(1/71) (1/113) (1/142) (1/226)
*1302 0.169 0.195 0.66 - 0.085 0.097 0.68 -
(12/71) (22/113) (12/142) (22/226)
*1401 0.028 0.053 0.71 - 0.014 0.027 0.72 -
(2/71) (6/113) (2/142) (6/226)
*1403 0.042 0.062 0.74 - 0.021 0.031 0.75 -
(3/71) (7/113) (3/142) (7/226)
*1405 0.056 0.062 1 - 0.028 0.031 1 -
(4/71) (7/113) (4/142) (7/226)
*1406 0.014 0.018 1 - 0.007 0.009 1 -
(1/71) (2/113) (1/142) (2/226)
*1501 0.183 0.106 0.14 - 0.092 0.058 0.21 -
(13/71) (12/113) (13/142) (13/226)
*1502 0.127 0.186 0.31 - 0.07 0.102 0.31 -
(9/71) (21/113) (10/142) (23/226)
*1602 0 0.035 0.16 - 0 0.018 0.3 -
(0/71) (4/113) (0/142) (4/226)
There was no significant association between HLA-DRB1
and SJS/TEN with ocular complications.
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552frequency: p<0.0005, Pc<0.005, OR=3.2). HLA-A*1101 was
inversely  associated  (carrier  frequency:  p<0.01,  Pc=0.07,
OR=0.23;  allele  frequency:  p<0.005,  Pc<0.05,  OR=0.22).
SJS/TEN patients in this study consisted of 40 previously
analyzed patients and 31 new patients. These results validate
the strong association between HLA-A*0206 and SJS/TEN
that we reported previously [13].
Table  2  shows  the  results  on  HLA-B  alleles.  HLA-
B*5901 exhibited a high odds ratio for SJS/TEN with ocular
complications (carrier frequency: p<0.05, Pc=0.42, OR=7.0;
allele frequency: p<0.05, Pc=0.46, OR=6.7). However, when
we corrected the p-value for the number of alleles detected
(n=29), the results ceased to be significant.
There was no association between HLA-C and SJS/TEN
with  ocular  complications  (Table  3).  There  was  also  no
significant association between HLA-DRB1 and SJS/TEN
with ocular complications (Table 4).
HLA-DQB1*0502  showed  a  tendency  of  negative
association with SJS/TEN with ocular complications (carrier
frequency: p<0.05, Pc=0.17, OR=0; allele frequency: p<0.05,
Pc=0.19, OR=0); Table 5). Although none of the 71 SJS/TEN
patients and 10 of the 117 healthy volunteers (8.5%) had the
HLA-DQB1*0502 allele, the correction of the p-value for the
number of alleles detected (n=14) rendered the result not
significant.
We  used  the  χ2-test  for  statistical  analysis  when  the
sample  number  was  10  and  more  than  10  and  used  the
Fischer’s exact test when the sample number was less than 10.
Carrier frequency is “frequency of the person with the allele
TABLE 5. HLA-DQB1 ALLELES AND SJS/TEN WITH OCULAR COMPLICATIONS.
HLA-DQB1
alleles
Carrier frequency Allele frequency
SJS (n=71) Normal
(n=113)
p Odds ratio SJS (n=142) Normal
(n=226)
p Odds ratio
*0201 0.014 0.009 1 - 0.007 0.004 1 -
(1/71) (1/113) (1/142) (1/226)
*0301 0.254 0.212 0.52 - 0.141 0.106 0.32 -
(18/71) (24/113) (20/142) (24/226)
*0302 0.169 0.177 0.89 - 0.085 0.093 0.78 -
(12/71) (20/113) (12/142) (21/226)
*0303 0.296 0.354 0.41 - 0.169 0.195 0.54 -
(21/71) (40/113) (24/142) (44/226)
*0401 0.197 0.239 0.51 - 0.106 0.128 0.51 -
(14/71) (27/113) (15/142) (29/226)
*0402 0.056 0.053 1 - 0.028 0.027 1 -
(4/71) (6/113) (4/142) (6/226)
*0501 0.113 0.097 0.81 - 0.056 0.053 1 -
(8/71) (11/113) (8/142) (12/226)
*0502 0 0.08 0.01 0 0 0.04 0.01 0
(0/71) (9/113) (0/142) (9/226)
*0503 0.085 0.062 0.57 - 0.042 0.031 0.57 -
(6/71) (7/113) (6/142) (7/226)
*0601 0.352 0.274 0.26 - 0.19 0.164 0.63 -
(25/71) (31/113) (26/142) (37/226)
*0602 0.155 0.106 0.33 - 0.078 0.058 0.45 -
(11/71) (12/113) (11/142) (13/226)
*0603 0.014 0.009 1 - 0.007 0.004 1 -
(1/71) (1/113) (1/142) (1/226)
*0604 0.169 0.195 0.66 - 0.085 0.097 0.68 -
(12/71) (22/113) (12/142) (22/226)
HLA-DQB1*0502 showed a tendency of negative association with SJS/TEN with ocular complications (carrier frequency:
p<0.05, Pc=0.17, OR=0; allele frequency: p<0.05, Pc=0.19, OR=0). Although none of the 71 SJS/TEN patients and 10 of the
117 healthy volunteers (8.5%) had the HLA-DQB1*0502 allele, the correction of the p-value for the number of alleles detected
(n=14) rendered the result not significant.
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553at the population level,” and allele frequency is “frequency of
alleles at the population level” [15].
DISCUSSION
Analysis  of  our  71  Japanese  patients  showed  that  HLA-
A*0206 was strongly associated with SJS/TEN with ocular
complications.  On  the  other  hand,  HLA-A*1101  was
negatively  associated.  We  postulate  that  the  decreased
B*5401 frequency in the patients is attributable to its linkage
disequilibrium  with  A*1101.  We  also  found  that  HLA-
B*5901 was weakly associated with SJS/TEN with ocular
complications although when we corrected the p-value for the
number of alleles detected, the result ceased to be significant.
We postulate that B*5901 could be a risk factor independent
of  A*0206  because  only  one  patient  had  both  alleles.
Interestingly, none of the 71 SJS/TEN patients but 10 of the
117  volunteers  (8.5%)  had  the  HLA-DQB1*0502  allele.
HLA-DQB1*0502 was also weakly associated with SJS/TEN
with ocular complications although correction of the p-value
for the number of alleles detected rendered the result not
significant.
Regarding HLA-class I, previous reports from the United
States [16] and France [17] showed that the HLA-B12 (HLA-
Bw44) antigen was significantly increased in Caucasian SJS
patients.  In  our  study  population,  we  did  not  find  an
association with HLA-B12 probably because in Caucasians,
the HLA-B12 antigen is primarily coded by HLA-B*4402
whereas in the Japanese, it is almost exclusively coded by
HLA-B*4403 [15]. HLA-A*0206, strongly associated with
SJS/TEN with ocular complications in the Japanese, is absent
in Caucasians. While we were unable to identify the causative
drug(s)  unequivocally,  we  suspect  that  antibiotics,  cold
remedies,  or  non-steroid  anti-inflammatory  drugs  were
involved in some of our patients. Limiting carbamazepine-
induced  SJS,  the  HLA-B*1502  allele  was  documented  to
show a very strong association [18].
With respect to HLA-class II, Power et al. [19] reported
that  HLA-DQB1*0601  was  associated  with  Caucasian
patients with ocular complications of SJS. In French SJS/TEN
patients, HLA-DR antigens (DR) was not associated at all
[16]. Different from the findings of others, we found that in
our  Japanese  patients,  there  is  no  significant  association
between SJS/TEN and HLA-DQB1*0601.
Thus, our findings suggest strong ethnic differences in
the association of SJS/TEN with HLA (Table 6). Because SJS/
TEN is a rare condition probably with a complex genetic
inheritance background, specific combinations of genes and
certain  environmental  factors  may  be  required  for  the
manifestation  of  this  rare  phenotype.  Since  the  strong
association of specific HLA antigens with SJS with ocular
complications  may  be  a  clue  to  understanding  its  basic
pathobiology, we are attempting to develop a reliable test for
identifying  individuals  susceptible  to  SJS  with  ocular
complications.
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